Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how?
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Bousquet, E. Bateman, A. Briggs, T. Clark, S. Pedersen, W. Busse (Montpellier, France; Cape Town, South Africa; Oxford, London, United Kingdom; Madison, United States Of America). Aiming for total control of asthma with salmeterol/fluticasone propionate (SFC), a cost effective option. Eur Respir J 2005; 26: Suppl. 49, 2769

Member's Comments

No comment yet.

Related content which might interest you: The cost-effectiveness of achieving asthma control with the combination products salmeterol/fluticasone propionate or formoterol/budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001 Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005 EXCEL: regular maintenance therapy with salmeterol/fluticasone propionate combination (SFC) reduces exacerbations more effectively than with formoterol/budesonide combination (FBC) Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004 Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Is overall asthma control being achieved? A hypothesis-generating study Source: Eur Respir J 2001; 17: 589-595 Year: 2001 Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Superiority of the ‘triple‘ therapy of salmeterol/fluticasone propionate (SFC) and tiotropium (TIO) vs. individual components in COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007 Salmeterol/fluticasone propionate combination (SFC) inhaler is associated with greater levels of compliance in children than other regular asthma medications Source: Eur Respir J 2002; 20: Suppl. 38, 431s Year: 2002 Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002 Salmeterol/fluticasone combination product (SFC) provides better asthma control compared to high dose fluticasone (FP) in symptomatic patients with asthma Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how? Year: 2005 The safety of double dose salmeterol/fluticasone proprionate (SFC) in adult asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004 Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002 Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost-saving versus a higher maintenance dose of B/F or salmeterol/fluticasone (S/F) Source: Eur Respir J 2006; 28: Suppl. 50, 214s Year: 2006 Achieving guideline-based asthma control: does the patient benefit? Source: Eur Respir J 2002; 20: 588-596 Year: 2002 Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β2agonists (LABA) + inhaled corticosteroids (ICS) Source: Eur Respir J 2003; 22: Suppl. 45, 312s Year: 2003 Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007 Improved patient compliance with salmeterol/fluticasone propionate combination (SFC) compared with regular long-acting β2 agonist (LAB) and inhaled steroid (IS) therapy Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002